274 related articles for article (PubMed ID: 30199223)
1. Development of Adenosine A
Zheng J; Zhang X; Zhen X
ACS Chem Neurosci; 2019 Feb; 10(2):783-791. PubMed ID: 30199223
[TBL] [Abstract][Full Text] [Related]
2. An overview of adenosine A2A receptor antagonists in Parkinson's disease.
Jenner P
Int Rev Neurobiol; 2014; 119():71-86. PubMed ID: 25175961
[TBL] [Abstract][Full Text] [Related]
3. Pharmacological interactions between adenosine A
Pinna A; Serra M; Marongiu J; Morelli M
Parkinsonism Relat Disord; 2020 Nov; 80 Suppl 1():S37-S44. PubMed ID: 33349579
[TBL] [Abstract][Full Text] [Related]
4. Design and development of 1,3,5-triazine-thiadiazole hybrids as potent adenosine A
Masih A; Singh S; Agnihotri AK; Giri S; Shrivastava JK; Pandey N; Bhat HR; Singh UP
Neurosci Lett; 2020 Sep; 735():135222. PubMed ID: 32619652
[TBL] [Abstract][Full Text] [Related]
5. A2A Adenosine Receptor Antagonists as Therapeutic Candidates: Are They Still an Interesting Challenge?
Cacciari B; Spalluto G; Federico S
Mini Rev Med Chem; 2018; 18(14):1168-1174. PubMed ID: 29692248
[TBL] [Abstract][Full Text] [Related]
6. Discovery of indolylpiperazinylpyrimidines with dual-target profiles at adenosine A2A and dopamine D2 receptors for Parkinson's disease treatment.
Shao YM; Ma X; Paira P; Tan A; Herr DR; Lim KL; Ng CH; Venkatesan G; Klotz KN; Federico S; Spalluto G; Cheong SL; Chen YZ; Pastorin G
PLoS One; 2018; 13(1):e0188212. PubMed ID: 29304113
[TBL] [Abstract][Full Text] [Related]
7. Discovery of novel 1,3,5-triazine as adenosine A
Masih A; Agnihotri AK; Srivastava JK; Pandey N; Bhat HR; Singh UP
J Biochem Mol Toxicol; 2021 Mar; 35(3):e22659. PubMed ID: 33156955
[TBL] [Abstract][Full Text] [Related]
8. Do caffeine and more selective adenosine A
Chen JF; Schwarzschild MA
Parkinsonism Relat Disord; 2020 Nov; 80 Suppl 1(Suppl 1):S45-S53. PubMed ID: 33349580
[TBL] [Abstract][Full Text] [Related]
9. An update on adenosine A2A receptors as drug target in Parkinson's disease.
Vallano A; Fernandez-Duenas V; Pedros C; Arnau JM; Ciruela F
CNS Neurol Disord Drug Targets; 2011 Sep; 10(6):659-69. PubMed ID: 21838670
[TBL] [Abstract][Full Text] [Related]
10. Targeting adenosine A2A receptors in Parkinson's disease.
Schwarzschild MA; Agnati L; Fuxe K; Chen JF; Morelli M
Trends Neurosci; 2006 Nov; 29(11):647-54. PubMed ID: 17030429
[TBL] [Abstract][Full Text] [Related]
11. Discovery of Novel and Selective Adenosine A
Tian S; Wang X; Li L; Zhang X; Li Y; Zhu F; Hou T; Zhen X
J Chem Inf Model; 2017 Jun; 57(6):1474-1487. PubMed ID: 28463561
[TBL] [Abstract][Full Text] [Related]
12. The Pharmacological Potential of Adenosine A
Mori A; Chen JF; Uchida S; Durlach C; King SM; Jenner P
Molecules; 2022 Apr; 27(7):. PubMed ID: 35408767
[TBL] [Abstract][Full Text] [Related]
13. How and why the adenosine A
Jenner P; Kanda T; Mori A
Int Rev Neurobiol; 2023; 170():73-104. PubMed ID: 37741697
[TBL] [Abstract][Full Text] [Related]
14. Progress in pursuit of therapeutic A2A antagonists: the adenosine A2A receptor selective antagonist KW6002: research and development toward a novel nondopaminergic therapy for Parkinson's disease.
Kase H; Aoyama S; Ichimura M; Ikeda K; Ishii A; Kanda T; Koga K; Koike N; Kurokawa M; Kuwana Y; Mori A; Nakamura J; Nonaka H; Ochi M; Saki M; Shimada J; Shindou T; Shiozaki S; Suzuki F; Takeda M; Yanagawa K; Richardson PJ; Jenner P; Bedard P; Borrelli E; Hauser RA; Chase TN;
Neurology; 2003 Dec; 61(11 Suppl 6):S97-100. PubMed ID: 14663020
[TBL] [Abstract][Full Text] [Related]
15. Istradefylline: adenosine A2A receptor antagonist to reduce "OFF" time in Parkinson's disease.
Paton DM
Drugs Today (Barc); 2020 Feb; 56(2):125-134. PubMed ID: 32163528
[TBL] [Abstract][Full Text] [Related]
16. Adenosine A2A-receptor antagonism and pathophysiology of Parkinson's disease and drug-induced movement disorders.
Kulisevsky J; Poyurovsky M
Eur Neurol; 2012; 67(1):4-11. PubMed ID: 22134373
[TBL] [Abstract][Full Text] [Related]
17. Istradefylline, a novel adenosine A2A receptor antagonist, for the treatment of Parkinson's disease.
Jenner P
Expert Opin Investig Drugs; 2005 Jun; 14(6):729-38. PubMed ID: 16004599
[TBL] [Abstract][Full Text] [Related]
18. The adenosine A(2A) receptor as an attractive target for Parkinson's disease treatment.
Chen JF
Drug News Perspect; 2003 Nov; 16(9):597-604. PubMed ID: 14702141
[TBL] [Abstract][Full Text] [Related]
19. Crystal structure of the adenosine A
Sun B; Bachhawat P; Chu ML; Wood M; Ceska T; Sands ZA; Mercier J; Lebon F; Kobilka TS; Kobilka BK
Proc Natl Acad Sci U S A; 2017 Feb; 114(8):2066-2071. PubMed ID: 28167788
[TBL] [Abstract][Full Text] [Related]
20. Can adenosine A
Kanda T; Jenner P
Parkinsonism Relat Disord; 2020 Nov; 80 Suppl 1():S21-S27. PubMed ID: 33349576
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
